REFERENCES
- Klaren V N, Kijlstra A. Toxoplasmosis, an overview with emphasis on ocular involvement. Ocul Immunol Inflamm 2002; 10: 1–26, [INFOTRIEVE], [CSA]
- Lopez J S, de Smet M D, Masur H, Mueller B U, Pizzo P A, Nussenblatt R B. Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol 1992; 113: 331–333, [INFOTRIEVE], [CSA]
- Pearson P A, Piracha A R, Sen H A, Jaffe G J. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology 1999; 106: 148–153, [INFOTRIEVE], [CROSSREF], [CSA]
- Hudde T, Althaus C, Schimkat M, Sundmacher R. [Treatment of toxoplasmosis retinochoroiditis with atovaquone in an immunocompetent patient]. Klin Monatsbl Augenheilkd 1996; 209: 232–236, [INFOTRIEVE], [CSA]
- Kessl J J, Lange B B, Merbitz-Zahradnik T, Zwicker K, Hill P, Meunier B, et al. Molecular basis for atovaquone binding to the cytochrome bc1 complex. J Biol Chem 2003; 278: 31312–31318, [INFOTRIEVE], [CROSSREF], [CSA]
- Araujo F G, Huskinson J, Remington J S. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother 1991; 35: 293–299, [INFOTRIEVE], [CSA]
- Katlama C, Mouthon B, Gourdon D, Lapierre D, Rousseau F. Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group. AIDS 1996; 10: 1107–1112, [INFOTRIEVE], [CSA]
- Romand S, Pudney M, Derouin F. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother 1993; 37: 2371–2378, [INFOTRIEVE], [CSA]
- Baggish A L, Hill D R. Antiparasitic agent atovaquone. Antimicrob Agents Chemother 2002; 46: 1163–1173, [INFOTRIEVE], [CROSSREF], [CSA]
- McFadden D C, Tomavo S, Berry E A, Boothroyd J C. Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol Biochem Parasitol 2000; 108: 1–12, [INFOTRIEVE], [CROSSREF], [CSA]